Imatinib activates pathological hypertrophy by altering myocyte calcium regulation

Clinical and Translational Science

Volumn 7, Issue 5, 2014, Pages 360-367

  Barr, Larry A ^a   Makarewich, Catherine A ^a   Berretta, Remus M ^a   Gao, Hui ^a   Troupes, Constantine D ^a   Woitek, Felix ^a   Recchia, Fabio ^a   Kubo, Hajime ^a   Force, Thomas ^a   Houser, Steven R ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium; Cancer pharmacology; Hypertrophy; Molecular biology

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM ION; CASPASE 3; GREEN FLUORESCENT PROTEIN; IMATINIB; PHOSPHOLAMBAN; PROTEIN SERINE THREONINE KINASE INHIBITOR; RYANODINE RECEPTOR; SERINE; TACROLIMUS; THREONINE; TRANSCRIPTION FACTOR NFAT; BENZAMIDE DERIVATIVE; CALCINEURIN; CALCIUM; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL DEATH; CONTROLLED STUDY; CYTOPLASM; DOSE RESPONSE; ENZYME ACTIVATION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE CELL; CARDIOMEGALY; CELL NUCLEUS; CYTOLOGY; DRUG EFFECTS; HEART VENTRICLE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEIN TRANSPORT; SPRAGUE DAWLEY RAT;

ANIMALS; APOPTOSIS; BENZAMIDES; CALCINEURIN; CALCIUM; CALCIUM SIGNALING; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CARDIOMEGALY; CELL NUCLEUS; HEART VENTRICLES; IMATINIB MESYLATE; MICE; MYOCYTES, CARDIAC; NFATC TRANSCRIPTION FACTORS; PHOSPHORYLATION; PIPERAZINES; PROTEIN TRANSPORT; PYRIMIDINES; RATS, SPRAGUE-DAWLEY;

EID: 84911812092     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12173     Document Type: Article

References (45)

1. Van Etten RA. Mechanisms of transformation by the Bcr-Abl oncogene: new perspectives in the post-imatinib era. Leuk Res. 2004; 28(Suppl. 1): 21-28.
2. Kantarjian HM, Giles F, Quintas-Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res. 2007; 13: 1089-1097.
3. Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, Bhatia R. Detection of Bcr-Abl kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood. 2005; 105: 2093-2098.
4. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005; 105: 2640-2653.
5. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006; 12: 908--916.
6. Park YH, Park HJ, Kim BS, Ha E, Jung KH, Yoon SH, Yim SV, Chung JH. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett. 2006; 243: 16-22.
7. Alihanoglu YI, Kaya Z, Ari H, Karaarslan S, Yildiz BS, Karanfil M, Yazici M, Boruban MC, Ozdemir K, Ulgen MS. Assessment of left ventricular systolic and diastolic function with conventional and tissue Doppler echocardiography imaging techniques in patients administered tyrosine kinase inhibitor. Turk Kardiyol Dern Ars. 2012; 40: 597--605.
8. Wolff NC, Ilaria RL, Jr. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood. 2001; 98: 2808-2816.
9. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009; 121: 227--252.
10. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the iris study. Blood. 2008; 111: 4022-4028.
11. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, Lassalle R, Marit G, Reiffers J, Begaud B, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007; 109: 3496-3499.
12. Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovas Res. 2006; 69: 318-328.
13. Mills GD, Kubo H, Harris DM, Berretta RM, Piacentino V, 3rd, Houser SR. Phosphorylation of phospholamban at threonine-17 reduces cardiac adrenergic contractile responsiveness in chronic pressure overload-induced hypertrophy. Am J Physiol Heart Circ Physiol. 2006; 291: 61-70.
14. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998; 93: 215-228.
15. Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun. 2004; 322: 1178-1191.
16. Gao H, Wang F, Wang W, Makarewich CA, Zhang H, Kubo H, Berretta RM, Barr LA, Molkentin JD, Houser SR. Ca2+ influx through l-type Ca2+ channels and transient receptor potential channels activates pathological hypertrophy signaling. J Mol Cell Cardiol. 2012; 53: 657-667.
17. Gaughan JP, Hefner CA, Houser SR. Electrophysiological properties of neonatal rat ventricular myocytes with alpha1-adrenergic-induced hypertrophy. Am J Physiol. 1998; 275: 577-590.
18. Simpson P, Savion S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Cross-striations, ultrastructure, and chronotropic response to isoproterenol. Circ Res. 1982; 50: 101-116.
19. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004; 114: 1308-1316.
20. Zhang H, Makarewich CA, Kubo H, Wang W, Duran JM, Li Y, Berretta RM, Koch WJ, Chen X, Gao E, et al. Hyperphosphorylation of the cardiac ryanodine receptor at serine 2808 is not involved in cardiac dysfunction after myocardial infarction. Circ Res. 2012; 110: 831-840.
21. Alibin CP, Kopilas MA, Anderson HD. Suppression of cardiac myocyte hypertrophy by conjugated linoleic acid: role of peroxisome proliferator-activated receptors alpha and gamma. J Biol Chem. 2008; 283: 10707-10715.
22. Anderson HD, Wang F, Gardner DG. Role of the epidermal growth factor receptor in signaling strain-dependent activation of the brain natriuretic peptide gene. J Biol Chem. 2004; 279: 9287-9297.
23. Silver LH, Hemwall EL, Marino TA, Houser SR. Isolation and morphology of calcium-tolerant feline ventricular myocytes. Am J Physiol. 1983; 245: 891-896.
24. Ohtsu H, Dempsey PJ, Frank GD, Brailoiu E, Higuchi S, Suzuki H, Nakashima H, Eguchi K, Eguchi S. Adam17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler Thromb Vasc Biol. 2006; 26: 133-137.
25. 2+ channel antagonist inhibits hypertrophic signaling without reducing cardiac contractility. Circ Res. 2012; 110: 669-674.
26. Chen X, Wilson RM, Kubo H, Berretta RM, Harris DM, Zhang X, Jaleel N, MacDonnell SM, Bearzi C, Tillmanns J, et al. Adolescent feline heart contains a population of small, proliferative ventricular myocytes with immature physiological properties. Circ Res. 2007; 100: 536-544.
27. Kubo H, Margulies KB, Piacentino V, 3rd, Gaughan JP, Houser SR. Patients with end-stage congestive heart failure treated with beta-adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance. Circulation. 2001; 104: 1012-1018.
28. Molkentin JD. Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res. 2000; 87: 731-738.
29. Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to caenorhabditis elegans cell death protein ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem. 1994; 269: 30761-30764.
30. Zhang T, Kohlhaas M, Backs J, Mishra S, Phillips W, Dybkova N, Chang S, Ling H, Bers DM, Maier LS, et al. CamkIIdelta isoforms differentially affect calcium handling but similarly regulate HDAC/MEF2 transcriptional responses. J Biol Chem. 2007; 282: 35078-35087.
31. MacDonnell SM, Weisser-Thomas J, Kubo H, Hanscome M, Liu Q, Jaleel N, Berretta R, Chen X, Brown JH, Sabri AK, et al. CaMKII negatively regulates calcineurin-NFAT signaling in cardiac myocytes. Circ Res. 2009; 105: 316-325.
32. Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res. 2010; 106: 21-34.
33. Marchan R, Bolt HM. Imatinib: the controversial discussion on cardiotoxicity induced by endoplasmic reticulum (ER) stress. Arch Toxicol. 2012; 86: 339-340.
34. Force T, Kerkela R. Cardiotoxicity of the new cancer therapeutics-mechanisms of, and approaches to, the problem. Drug Discov Today. 2008; 13: 778-784.
35. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007; 7: 332-344.
36. Saad SY, Alkharfy KM, Arafah MM. Cardiotoxic effects of arsenic trioxide/imatinib mesilate combination in rats. J Pharm Pharmacol. 2006; 58: 567-573.
37. Herman EH, Knapton A, Rosen E, Thompson K, Rosenzweig B, Estis J, Agee S, Lu QA, Todd JA, Lipshultz S, et al. A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat. Toxicol Pathol. 2011; 39: 1091-1106.
38. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007; 370: 2011-2019.
39. Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, Hynes J, Patyna S, Jessen BA. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci. 2008; 106: 153-161.
40. Tomaselli GF, Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res. 1999; 42: 270-283.
41. Janse MJ. Electrophysiological changes in heart failure and their relationship to arrhythmogenesis. Cardiovas Res. 2004; 61: 208-217.
42. Weber CR, Ginsburg KS, Philipson KD, Shannon TR, Bers DM. Allosteric regulation of Na/Ca exchange current by cytosolic Ca in intact cardiac myocytes. J Gen Physiol. 2001; 117: 119-131.
43. Grimm M, Brown JH. Beta-adrenergic receptor signaling in the heart: role of CamkII. J Mol Cell Cardiol. 2010; 48: 322-330.
44. Fernandez A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest. 2007; 117: 4044-4054.
45. 2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest. 2007; 117: 2431-2444.